The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes.
暂无分享,去创建一个
E. Antman | R. Giugliano | E. Braunwald | C. Cannon | D. Morrow | S. Murphy | C. Gibson | S. Ahmed | C. Gibson
[1] J. Núñez,et al. Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial. , 2007, International journal of cardiology.
[2] F. Veglia,et al. N-Acetylcysteine and Contrast-Induced Nephropathy in Primary Angioplasty , 2006 .
[3] P. Parfrey,et al. Preventing Nephropathy Induced by Contrast Medium , 2006 .
[4] J. Dubois-Randé,et al. Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study). , 2004, The American journal of cardiology.
[5] B. Brenner,et al. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. , 2004, Kidney international.
[6] E. Antman,et al. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. , 2004, European heart journal.
[7] R. Gupta,et al. The renal patient with coronary artery disease: current concepts and dilemmas. , 2004, Journal of the American College of Cardiology.
[8] Robert M Califf,et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. , 2004, The New England journal of medicine.
[9] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[10] E. Topol,et al. Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. , 2004, The American journal of cardiology.
[11] J. Rumsfeld,et al. Renal insufficiency and mortality from acute coronary syndromes. , 2004, American heart journal.
[12] N. Lamblin,et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. , 2004, European heart journal.
[13] J. J. Griffin,et al. Impact of Renal Insufficiency in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction , 2003, Circulation.
[14] E. Antman,et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. , 2003, Journal of the American College of Cardiology.
[15] Bertram L Kasiske,et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.
[16] W. McClellan,et al. Renal insufficiency and anemia are independent risk factors for death among patients with acute myocardial infarction. , 2003, Kidney international.
[17] C. Herzog,et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. , 2003, JAMA.
[18] G. Eknoyan,et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.
[19] J. Cooper,et al. Renal function and risk stratification in acute coronary syndromes. , 2003, The American journal of cardiology.
[20] E. Braunwald,et al. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). , 2002, The American journal of cardiology.
[21] C. Camargo,et al. Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction. , 2002, American heart journal.
[22] M. Mcclellan,et al. Association of Renal Insufficiency with Treatment and Outcomes after Myocardial Infarction in Elderly Patients , 2002, Annals of Internal Medicine.
[23] R. Califf,et al. Prognostic Implications of Abnormalities in Renal Function in Patients With Acute Coronary Syndromes , 2002, Circulation.
[24] R. Califf,et al. Outcomes of Patients With Chronic Renal Insufficiency in the Bypass Angioplasty Revascularization Investigation , 2002, Circulation.
[25] Ethan M Balk,et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[26] S. Yusuf,et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.
[27] W. Bloembergen,et al. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. , 2001, Journal of the American Society of Nephrology : JASN.
[28] E. Braunwald,et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. , 2001, The New England journal of medicine.
[29] I. Palacios,et al. Effectiveness of and adverse events after percutaneous coronary intervention in patients with mild versus severe renal failure. , 2001, The American journal of cardiology.
[30] E. Antman,et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.
[31] A. Skene,et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. , 2000, Circulation.
[32] A. Charlesworth,et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. , 2000, Circulation.
[33] E. Antman,et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.
[34] C. Wanner,et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.
[35] E. Braunwald,et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. , 1998, Circulation.
[36] A. Donker,et al. Endothelial dysfunction and pathogenesis of diabetic angiopathy. , 1997, Cardiovascular research.
[37] S. Cobbe. Thrombolysis in myocardial infarction , 1994, BMJ.